- Home
- EMBC vs DYN Comparison
EMBC vs DYN Comparison
Compare EMBC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMBC
- DYN
- Stock Information
- Founded
- EMBC 1924
- DYN 1984
- Country
- EMBC United States
- DYN United States
- Employees
- EMBC N/A
- DYN N/A
- Industry
- EMBC Medical/Dental Instruments
- DYN Medicinal Chemicals and Botanical Products
- Sector
- EMBC Health Care
- DYN Health Care
- Exchange
- EMBC Nasdaq
- DYN Nasdaq
- Market Cap
- EMBC 716.2M
- DYN 848.8M
- IPO Year
- EMBC N/A
- DYN 2020
- Fundamental
- Price
- EMBC $11.97
- DYN $11.41
- Analyst Decision
- EMBC Hold
- DYN Strong Buy
- Analyst Count
- EMBC 3
- DYN 12
- Target Price
- EMBC $17.67
- DYN $47.00
- AVG Volume (30 Days)
- EMBC 445.0K
- DYN 2.9M
- Earning Date
- EMBC 05-09-2025
- DYN 05-08-2025
- Dividend Yield
- EMBC 5.02%
- DYN N/A
- EPS Growth
- EMBC N/A
- DYN N/A
- EPS
- EMBC 0.89
- DYN N/A
- Revenue
- EMBC $1,079,500,000.00
- DYN N/A
- Revenue This Year
- EMBC N/A
- DYN N/A
- Revenue Next Year
- EMBC $0.99
- DYN N/A
- P/E Ratio
- EMBC $13.36
- DYN N/A
- Revenue Growth
- EMBC N/A
- DYN N/A
- 52 Week Low
- EMBC $10.12
- DYN $6.36
- 52 Week High
- EMBC $21.48
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- EMBC 46.46
- DYN 55.69
- Support Level
- EMBC $12.08
- DYN $9.17
- Resistance Level
- EMBC $13.45
- DYN $12.47
- Average True Range (ATR)
- EMBC 0.59
- DYN 0.96
- MACD
- EMBC 0.13
- DYN 0.13
- Stochastic Oscillator
- EMBC 40.75
- DYN 67.88
About EMBC Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.